These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1084 related articles for article (PubMed ID: 23839242)

  • 1. Evaluating cell lines as tumour models by comparison of genomic profiles.
    Domcke S; Sinha R; Levine DA; Sander C; Schultz N
    Nat Commun; 2013; 4():2126. PubMed ID: 23839242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular characterization of 7 new established cell lines from high grade serous ovarian cancer.
    Kreuzinger C; Gamperl M; Wolf A; Heinze G; Geroldinger A; Lambrechts D; Boeckx B; Smeets D; Horvat R; Aust S; Hamilton G; Zeillinger R; Cacsire Castillo-Tong D
    Cancer Lett; 2015 Jul; 362(2):218-28. PubMed ID: 25862976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic determinants of FOXM1 overexpression in epithelial ovarian cancer and functional contribution to cell cycle progression.
    Barger CJ; Zhang W; Hillman J; Stablewski AB; Higgins MJ; Vanderhyden BC; Odunsi K; Karpf AR
    Oncotarget; 2015 Sep; 6(29):27613-27. PubMed ID: 26243836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mucins and Truncated
    Coelho R; Marcos-Silva L; Mendes N; Pereira D; Brito C; Jacob F; Steentoft C; Mandel U; Clausen H; David L; Ricardo S
    Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30011875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer.
    Karlan BY; Dering J; Walsh C; Orsulic S; Lester J; Anderson LA; Ginther CL; Fejzo M; Slamon D
    Gynecol Oncol; 2014 Feb; 132(2):334-42. PubMed ID: 24368280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-resolution gene copy number and expression profiling of human chromosome 22 in ovarian carcinomas.
    Benetkiewicz M; Wang Y; Schaner M; Wang P; Mantripragada KK; Buckley PG; Kristensen G; Børresen-Dale AL; Dumanski JP
    Genes Chromosomes Cancer; 2005 Mar; 42(3):228-37. PubMed ID: 15578687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling.
    Bashashati A; Ha G; Tone A; Ding J; Prentice LM; Roth A; Rosner J; Shumansky K; Kalloger S; Senz J; Yang W; McConechy M; Melnyk N; Anglesio M; Luk MT; Tse K; Zeng T; Moore R; Zhao Y; Marra MA; Gilks B; Yip S; Huntsman DG; McAlpine JN; Shah SP
    J Pathol; 2013 Sep; 231(1):21-34. PubMed ID: 23780408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene expression profiles of luteal phase fallopian tube epithelium from BRCA mutation carriers resemble high-grade serous carcinoma.
    Tone AA; Begley H; Sharma M; Murphy J; Rosen B; Brown TJ; Shaw PA
    Clin Cancer Res; 2008 Jul; 14(13):4067-78. PubMed ID: 18593983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer.
    Zorn KK; Bonome T; Gangi L; Chandramouli GV; Awtrey CS; Gardner GJ; Barrett JC; Boyd J; Birrer MJ
    Clin Cancer Res; 2005 Sep; 11(18):6422-30. PubMed ID: 16166416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver.
    Emmanuel C; Chiew YE; George J; Etemadmoghadam D; Anglesio MS; Sharma R; Russell P; Kennedy C; Fereday S; Hung J; Galletta L; Hogg R; Wain GV; Brand A; Balleine R; MacConaill L; Palescandolo E; Hunter SM; Campbell I; Dobrovic A; Wong SQ; Do H; Clarke CL; Harnett PR; Bowtell DD; deFazio A;
    Clin Cancer Res; 2014 Dec; 20(24):6618-30. PubMed ID: 25316818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular profiling uncovers a p53-associated role for microRNA-31 in inhibiting the proliferation of serous ovarian carcinomas and other cancers.
    Creighton CJ; Fountain MD; Yu Z; Nagaraja AK; Zhu H; Khan M; Olokpa E; Zariff A; Gunaratne PH; Matzuk MM; Anderson ML
    Cancer Res; 2010 Mar; 70(5):1906-15. PubMed ID: 20179198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes.
    Hunter SM; Anglesio MS; Ryland GL; Sharma R; Chiew YE; Rowley SM; Doyle MA; Li J; Gilks CB; Moss P; Allan PE; Stephens AN; Huntsman DG; deFazio A; Bowtell DD; ; Gorringe KL; Campbell IG
    Oncotarget; 2015 Nov; 6(35):37663-77. PubMed ID: 26506417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing breast cancer cell lines as tumour models by comparison of mRNA expression profiles.
    Vincent KM; Findlay SD; Postovit LM
    Breast Cancer Res; 2015 Aug; 17(1):114. PubMed ID: 26289960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low levels of IGFBP7 expression in high-grade serous ovarian carcinoma is associated with patient outcome.
    Gambaro K; Quinn MC; Cáceres-Gorriti KY; Shapiro RS; Provencher D; Rahimi K; Mes-Masson AM; Tonin PN
    BMC Cancer; 2015 Mar; 15():135. PubMed ID: 25886299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact on high-grade serous ovarian cancer of obesity and lipid metabolism-related gene expression patterns: the underestimated driving force affecting prognosis.
    Cuello MA; Kato S; Liberona F
    J Cell Mol Med; 2018 Mar; 22(3):1805-1815. PubMed ID: 29266765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic analysis reveals a lncRNA-mRNA co-expression network associated with platinum resistance in high-grade serous ovarian cancer.
    Fang L; Wang H; Li P
    Invest New Drugs; 2018 Apr; 36(2):187-194. PubMed ID: 29082457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a Bioluminescent BRCA1-Deficient Xenograft Model of Disseminated, High-Grade Serous Ovarian Cancer.
    Shen YT; Wang L; Evans JC; Allen C; Piquette-Miller M
    Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31117198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nicotinamide N-methyltransferase overexpression may be associated with poor prognosis in ovarian cancer.
    Harmankaya İ; Akar S; Uğraş S; Güler AH; Ezveci H; Aydoğdu M; Çelik Ç
    J Obstet Gynaecol; 2021 Feb; 41(2):248-253. PubMed ID: 32285726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrative proteogenomic analyses of human tumours identifies ADNP as a novel oncogenic mediator of cell cycle progression in high-grade serous ovarian cancer with poor prognosis.
    Karagoz K; Mehta GA; Khella CA; Khanna P; Gatza ML
    EBioMedicine; 2019 Dec; 50():191-202. PubMed ID: 31767542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted Genomic Sequencing Reveals Novel
    Jung YY; Woo HY; Kim HS
    Anticancer Res; 2019 Jun; 39(6):2883-2889. PubMed ID: 31177126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 55.